Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2576572 | 0.85 | P4HB (0.36) | P4HBRAB9ANPC1KDM4DMAPT | |
| SCHEMBL2305458 | 0.84 | P4HB (0.40) | P4HBRAB9ANPC1MAPTMAPK1 | |
| SCHEMBL3327533 | 0.80 | P4HB (0.41) | P4HBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL2307433 | 0.80 | P4HB (0.38) | P4HBRAB9ANPC1KDM4DMAPT | |
| SCHEMBL2307293 | 0.78 | P4HB (0.36) | P4HBMAPTSMN1; SMN2KDM4EHTT | |
| SCHEMBL281099 | 0.78 | P4HB (0.47) | P4HBKDM4DMAPTSMN1; SMN2KDM4E | |
| SCHEMBL3330531 | 0.77 | P4HB (0.36) | P4HBRAB9ANPC1 | |
| SCHEMBL2304503 | 0.75 | GNRHR (0.37) | P4HBRAB9ANPC1KDM4DMAPT | |
| SCHEMBL2302916 | 0.75 | P4HB (0.36) | P4HBMAPTSMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL281799 | 0.74 | P4HB (0.35) | P4HBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | SCN3A, SCN1B, SCN2B | P4HB 1324/4885RAB9A 1449/4885NPC1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.